IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...
BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization ...
US biosimilar 'void' spells trouble as biologic patent expirations loom, IQVIA report says
While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for ...
BTIG analyst David Larsen adjusted the firm's stance on IQVIA Holdings (NYSE:IQV), moving from a Buy rating to Neutral. The $36.5 billion market cap company, currently trading near its 52-week low at ...
Barclays lowered the firm’s price target on Iqvia (IQV) to $235 from $255 and keeps an Overweight rating on the shares. The firm says the life ...
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia ...
Dynamic Advisor Solutions LLC lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 9.1% in the ...
Given forthcoming changes to Medicare Part D plans under the Inflation Reduction Act, CMS should collect and publish ...
Concussions were down 17 percent from 2023 and were the lowest on record since the league started tracking data in 2015.
Evaluate the expected performance of IQVIA (IQV) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback